VEGF-A splicing: the key to anti-angiogenic therapeutics? (original) (raw)

• Mendel, D. B. et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 9, 327–337 (2003).
  CAS PubMed Google Scholar
• Motzer, R. J. et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115–124 (2007).
  Article CAS PubMed Google Scholar
• Hurwitz, H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335–2342 (2004).
  CAS PubMed Google Scholar
• Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. 29, 10–14 (2002).
  Article CAS PubMed Google Scholar
• Ferrara, N. & Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Comm. 161, 851–858 (1989).
  Article CAS PubMed Google Scholar
• Senger, D. R. et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983–985 (1983).
  Article CAS PubMed Google Scholar
• Keck, P. J. et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246, 1309–1312 (1989).
  CAS PubMed Google Scholar
• Venables, J. P. E. Alternative Splicing in Cancer (Transworld Research Network, Kerala, 2006).
  Google Scholar
• Ferrara, N. et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380, 439–442 (1996).
  Article CAS PubMed Google Scholar
• Ferrara, N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581–611 (2004).
  Article CAS PubMed Google Scholar
• Bates, D. O. et al. VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123–4131 (2002).
  CAS PubMed Google Scholar
• Perrin, R. M. et al. Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48, 2422–2427 (2005).
  Article CAS PubMed Google Scholar
• Nowak, D. G., et al. Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by known splicing and growth factors. J. Cell Sci. (in the press).
• Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389–395 (2000).
  Article CAS PubMed Google Scholar
• Olsson, A. -K., Dimberg, A., Kreuger, J. & Claesson-Welsh, L. VEGF receptor signalling-in control of vascular function. Nature Rev. Mol. Cell Biol. 7, 359–371 (2006).
  Article CAS Google Scholar
• Kerbel, R. S. Tumor angiogenesis. N. Engl. J. Med. 358, 2039–2049 (2008).
  CAS Google Scholar
• Bevan, H. S., Harper, S. J. & Bates, D. O. in Angiogenesis: Basic Science and Clinical Applications (eds Maragoudakis, M. E. & Papadimitriou, E.) 1–26 (Transworld Research Network, Kerala, 2007).
  Google Scholar
• Bevan, H. S. et al. The alternatively spliced anti-angiogenic family of VEGF isoforms, VEGFxxxb, in human kidney development. Nephron Physiol. (in the press).
• Cui, T. G. et al. Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein. Am. J. Physiol. Renal Physiol. 286, F767–F773 (2004).
  Article CAS PubMed Google Scholar
• Varey, A. H. et al. VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer 98, 1366–1379 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Gopi, S. S., Zadeh, M. H., Harper, S. J., Bates, D. O. & Gillatt, G. A. Expression of anti-angiogenic isoform, VEGF165b in transitional cell carcinoma of bladder. BJU Int. 101, 29–30 (2008).
  Google Scholar
• Cebe-Suarez, S. et al. Orf virus VEGF-E NZ2 promotes paracellular NRP-1/VEGFR-2 coreceptor assembly via the peptide RPPR. FASEB J. (in the press).
• Ruch, C., Skiniotis, G., Steinmetz, M. O., Walz, T. & Ballmer-Hofer, K. Structure of a VEGF–VEGF receptor complex determined by electron microscopy. Nature Struct. Mol. Biol. 14, 249–250 (2007).
  Article CAS Google Scholar
• Burgess, A. W. et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541–552 (2003).
  Article CAS PubMed Google Scholar
• Kawamura, H., Li, X., Harper, S. J., Bates, D. O. & Claesson-Welsh, L. VEGF-A165b is a weak in vitro agonist for VEGF receptor-2 due to lack of co-receptor binding and deficient regulation of kinase activity. Cancer Res. 68, 4683–4692 (2008).
  Article CAS PubMed Google Scholar
• Cebe Suarez, S. et al. A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cell. Mol. Life Sci. 63, 2067–2077 (2006).
  Article CAS PubMed Google Scholar
• Xia, P. et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J. Clin. Invest. 98, 2018–2026 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Takahashi, T., Ueno, H. & Shibuya, M. VEGF activates protein kinase C-dependent, but Ras-independent Raf–MEK–MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18, 2221–2230 (1999).
  Article CAS PubMed Google Scholar
• Lamoreaux, W. J., Fitzgerald, M., Reiner, A., Hasty, K. A. & Charles, S. T. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc. Res. 55, 29–42 (1998).
  Article CAS PubMed Google Scholar
• Lambrechts, D. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nature Genet. 34, 383–394 (2003).
  Article CAS PubMed Google Scholar
• Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53–67 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Eremina, V. et al. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med. 358, 1129–1136 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Sugimoto, H. et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J. Biol. Chem. 278, 12605–12608 (2003).
  Article CAS PubMed Google Scholar
• Foster, R. R. et al. Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am. J. Physiol. Renal Physiol. 284, F1263–F1273 (2003).
  Article CAS PubMed Google Scholar
• Foster, R. R., Saleem, M. A., Mathieson, P. W., Bates, D. O. & Harper, S. J. Vascular endothelial growth factor and nephrin interact and reduce apoptosis in human podocytes. Am. J. Physiol. Renal Physiol. 288, F48–F57 (2005).
  Article CAS PubMed Google Scholar
• Woolard, J. et al. VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822–7835 (2004).
  Article CAS PubMed Google Scholar
• Rennel, E. S. et al. The endogenous anti-angiogenic VEGF isoform, VEGF165b inhibits human tumour growth in mice. Br. J. Cancer 98, 1250–1257 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Konopatskaya, O., Churchill, A. J., Harper, S. J., Bates, D. O. & Gardiner, T. A. VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularisation in mice. Mol. Vis. 12, 626–632 (2006).
  CAS PubMed Google Scholar
• Rennel, E. S., et al. Recombinant human vascular endothelial growth factor (VEGF165b) protein is an effective anti-cancer agent in mice. Eur. J. Cancer 44, 1883–1894 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Ku, D. D., Zaleski, J. K., Liu, S. & Brock, T. A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 265, H586–H592 (1993).
  Article CAS Google Scholar
• Bates, D. O. & Curry, F. E. Vascular endothelial growth factor increases hydraulic conductivity of isolated perfused microvessels. Am. J. Physiol. Heart Circ. Physiol. 271, H2520–H2528 (1996).
  Article CAS Google Scholar
• Ferrara, N., Houck, K. A., Jakeman, L. B., Winer, J. & Leung, D. W. The vascular endothelial growth factor family of polypeptides. J. Cell Biochem. 47, 211–218 (1991).
  Article CAS PubMed Google Scholar
• Mitchell, C. A. et al. Unique vascular phenotypes following over-expression of individual VEGF-A isoforms from the developing lens. Angiogenesis 9, 209–224 (2006).
  Article PubMed Google Scholar
• Glass, C. A., Harper, S. J. & Bates, D. O. The anti-angiogenic VEGF isoform VEGF165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. J. Physiol. 572, 243–257 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Qiu, Y. et al. Mammary alveolar development during lactation is inhibited by the endogenous antiangiogenic growth factor isoform, VEGF165b. FASEB J. 22, 1104–1112 (2008).
  Article CAS PubMed Google Scholar
• Budge, J. R., Fryer, J. D. & Bates, D. O. Intraperitoneal administration of recombinant human VEGF165b inhibits dissemination of metatatic melanoma cells in vivo. Microcirculation 17, 18–19 (2008).
  Google Scholar
• Pritchard-Jones, R. O. et al. Expression of VEGFxxxb, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer 97, 223–230 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Diaz, R. et al. p73 isoforms affect VEGF, VEGF165b and PEDF expression in human colorectal tumors: VEGF165b downregulation as a marker of poor prognosis. Int. J. Cancer 123, 1060–1067 (2008).
  Article CAS PubMed Google Scholar
• Magnussen, A. et al. VEGF165b is more potent at inhibiting endothelial cell migration than Pegabtanib and is cytoprotective for retinal pigmented epithelial cells. FASEB J. 22, 746.14 (2008).
• Baffert, F., L. T. et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am. J. Physiol. Heart Circ. Physiol. 290, H547–H559 (2006).
  Article CAS PubMed Google Scholar
• Lee, S. et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell 130, 691–703 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Ghigna, C. et al. in Alternative Splicing in Cancer (ed. Venables, J.P.) 197–208 (Transworld Research Network, Kerala, 2006).
  Google Scholar
• Muro, A. F., Iaconcig, A. & Baralle, F. E. Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5′ splicing site. FEBS Lett. 437, 137–141 (1998).
  Article CAS PubMed Google Scholar
• Schaal, T. D. & Maniatis, T. Multiple distinct splicing enhancers in the protein-coding sequences of a constitutively spliced pre-mRNA. Mol. Cell Biol. 19, 261–273 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Venables, J. P. Aberrant and alternative splicing in cancer. Cancer Res. 64, 7647–7654 (2004).
  Article CAS PubMed Google Scholar
• Caceres, J. F. & Kornblihtt, A. R. Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet. 18, 186–193 (2002).
  Article CAS PubMed Google Scholar
• Neufeld, G. et al. Similarities and differences between the vascular endothelial growth factor (VEGF) splice variants. Cancer Metastasis Rev. 15, 153–158 (1996).
  Article CAS PubMed Google Scholar
• Amir-Ahmady, B., Boutz, P. L., Markovtsov, V., Phillips, M. L. & Black, D. L. Exon repression by polypyrimidine tract binding protein. RNA 11, 699–716 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Coles, L. S. et al. A multi-protein complex containing cold shock domain (Y-box) and polypyrimidine tract binding proteins forms on the vascular endothelial growth factor mRNA. Potential role in mRNA stabilization. Eur. J. Biochem. 271, 648–660 (2004).
  Article CAS PubMed Google Scholar
• Bakkour, N. et al. Small-molecule inhibition of HIV pre-mRNA splicing as a novel antiretroviral therapy to overcome drug resistance. PLoS Pathog. 3, 1530–1539 (2007).
  Article CAS PubMed Google Scholar
• Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90, 10705–10709 (1993).
  Article CAS PubMed PubMed Central Google Scholar
• Kou, B. et al. In vivo inhibition of tumor angiogenesis by a soluble VEGFR-2 fragment. Exp. Mol. Pathol. 76, 129–137 (2004).
  Article CAS PubMed Google Scholar
• Jin, P. et al. Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis. Arthritis Res. Ther. 10, R73 (2008).
  Article PubMed PubMed Central Google Scholar
• Gagnon, M. L. et al. Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity. Proc. Natl Acad. Sci. USA 97, 2573–2578 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Saarela, J., Ylikarppa, R., Rehn, M., Purmonen, S. & Pihlajaniemi, T. Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol. 16, 319–328 (1998).
  Article CAS PubMed Google Scholar
• Mundel, T. M. & Kalluri, R. Type IV collagen-derived angiogenesis inhibitors. Microvasc. Res. 74, 85–89 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Bates, D. O. & Harper, S. J. Therapeutic potential of inhibitory VEGF splice variants. Fut. Oncol. 1, 467–473 (2005).
  Article CAS Google Scholar
• Jin, W. & Cote, G.J. Enhancer-dependent splicing of _FGFR1_α-exon is repressed by RNA interference-mediated down-regulation of SRp55. Cancer Res. 64, 8901–8905 (2004).
  Article CAS PubMed Google Scholar
• Folkman, J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann. Surg. 175, 409–416 (1972).
  Article CAS PubMed PubMed Central Google Scholar
• Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677–684 (2003).
  Article CAS PubMed Google Scholar
• Whittle, C., Gillespie, K., Harrison, R., Mathieson, P. W. & Harper, S. J. Heterogeneous vascular endothelial growth factor (VEGF) isoform mRNA and receptor mRNA expression in human glomeruli, and the identification of VEGF148 mRNA, a novel truncated splice variant. Clin. Sci. (Lond.) 97, 303–312 (1999).
  Article CAS Google Scholar
• Hirose, Y., Tacke, R. & Manley, J. L. Phosphorylated RNA polymerase II stimulates pre-mRNA splicing. Genes Dev. 13, 1234–1239 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Koenigsberger, C., Chicca, J. J. 2nd, Amoureux, M. C., Edelman, G. M. & Jones, F. S. Differential regulation by multiple promoters of the gene encoding the neuron-restrictive silencer factor. Proc. Natl Acad. Sci. USA 97, 2291–2296 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Starovasnik, M. A. et al. Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states. J. Mol. Biol. 293, 531–544 (1999).
  Article CAS PubMed Google Scholar
• Muller, Y. A., Christinger, H. W., Keyt, B. A. & de Vos, A. M. The crystal structure of vascular endothelial growth factor (VEGF) refined to 1.93 Å resolution: multiple copy flexibility and receptor binding. Structure 5, 1325–1338 (1997).
  Article CAS PubMed Google Scholar
• Fairbrother, W. J., Champe, M. A., Christinger, H. W., Keyt, B. A. & Starovasnik, M. A. Solution structure of the heparin-binding domain of vascular endothelial growth factor. Structure 6, 637–648 (1998).
  Article CAS PubMed Google Scholar
• Keck, R. G., Berleau, L., Harris, R. & Keyt, B. A. Disulfide structure of the heparin binding domain in vascular endothelial growth factor: characterization of posttranslational modifications in VEGF. Arch. Biochem. Biophys. 344, 103–113 (1997).
  Article CAS PubMed Google Scholar
• Claffey, K. P., Senger, D. R. & Spiegelman, B. M. Structural requirements for dimerization, glycosylation, secretion, and biological function of VPF/VEGF. Biochim. Biophys. Acta Prot. Struct. Mol. Enzymol. 1246, 1–9 (1995).
  Article Google Scholar